Shanghai Zhongshan Hospital is conducting an interventional study, to assess the safety and outcome of treating confirmed ITP patients, at least 15 years of age or older, with a combination of hydroxychloroquine (HCQ) plus corticosteroids who are positive for anti-nuclear antibodies (ANA). Hydroxychloroquine (HCQ) has an immune modulating role on a variety of immune cells.
Participants will receive prednisone daily for six weeks, with or without HCQ which they will receive twice a day for 1 year.
Additional inclusion criteria include having a platelet count less than 30,000 with no bleeding symptoms, or less than 50,000 with bleeding symptoms.
China
Status: Actively Recruiting